WEBULL
WebtradeDownload

Core Scientific (CORZ), Why Is Its Latest Update Drawing Attention?

Simply Wall St · 1d ago

What Core Scientific’s New Credit Facilities Mean For Investors

Core Scientific (CORZ) has secured $600 million in senior secured credit facilities, a move that increases liquidity and reshapes its capital structure at a time when digital asset infrastructure is evolving quickly.

The package combines a $100 million revolving credit facility with a $500 million letter of credit facility. For you as an investor, the key point is not just the size of the financing but also how it changes the company’s access to cash and support for future projects.

Management expects the facilities to release about $300 million of restricted cash. That is a sizeable shift in available funds that could influence how Core Scientific approaches working capital, power agreements and potential growth initiatives in the coming years.

Over the past year Core Scientific’s share price has been volatile, with the 7 day share price return of 8.36% contrasting with a 30 day decline of 14.85% and a 90 day decline of 34.11%. At the same time, the 1 year total shareholder return of 31.35% points to stronger longer term momentum around the stock.

Spot opportunities around Core Scientific’s financing move by comparing it with a curated group of 21 cryptocurrency and blockchain stocks that are also tied to digital asset infrastructure and blockchain exposure.

Bulls see Core Scientific’s new $600 million credit package as fuel for growth, while bears focus on recent share price weakness and ongoing losses. Which side does the valuation lean toward next?

Most Popular Narrative: 51.8% Undervalued

The most followed narrative on Core Scientific pegs fair value at $37.13 per share compared with the last close of $17.89, which frames the credit facilities against a much higher long term earnings story.

The analysts have a consensus price target of $37.12 for Core Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.

We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Read the complete narrative.

Analysts are not just guessing. Their fair value hinges on steep revenue expansion, a swing from heavy losses to profits and a richer earnings multiple than the wider software sector. Curious how those ingredients combine to support a value that is more than double today’s price?

Result: Fair Value of $37.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Core Scientific’s story can shift quickly if its reliance on large counterparties like CoreWeave and AMD is tested, or if execution on new HPC capacity falls behind expectations.

Find out about the key risks to this Core Scientific narrative.

Another View On Core Scientific’s Valuation

There is a clear gap between the analyst fair value on Core Scientific and what the market is paying today. On a P/S of 13.1x versus 4x for the US Software industry and 2.4x for peers, and a fair ratio of 6.1x, the stock screens as expensive. Is the growth story strong enough to justify paying more than double that fair ratio?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:CORZ P/S Ratio as at Sep 2026
NasdaqGS:CORZ P/S Ratio as at Sep 2026

Next Steps

The mix of optimism and concern around Core Scientific is clear, so act quickly by reviewing the underlying numbers, risks and potential rewards for yourself. To see the balance of sentiment in one place, take a closer look at the 1 key reward and 3 important warning signs.

Looking For More Investment Ideas Beyond Core Scientific?

If you only focus on Core Scientific, you might miss other compelling setups. Use the Simply Wall Street Screener to uncover fresh opportunities that fit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.